Decongestant Use in Children ≈ 7 Years Old

Oral Pseudoephedrine (Preferred Option)

• Pseudoephedrine is the most effective oral decongestant and is generally safe and well‑tolerated in children older than 6 years when dosed appropriately 1.
• The medication is kept behind the pharmacy counter because it can be used as a methamphetamine precursor, but it remains readily obtainable with proper identification [1][2][3][4].
• Clinicians should monitor for stimulatory side effects such as insomnia, irritability, hyperactivity, and palpitations; these events are uncommon at recommended doses 1.
• Use with particular caution in children receiving stimulant therapy for ADHD, as concomitant use may increase adverse events [1][2]3.
• Pseudoephedrine should be avoided in children with underlying cardiovascular disease, hyperthyroidism, closed‑angle glaucoma, or bladder‑neck obstruction [1][2][3][4].

Phenylephrine (Not Recommended)

• Phenylephrine undergoes extensive gut metabolism, and its efficacy as an oral decongestant in children has not been well established [1][2][3][4].
• Current evidence does not support phenylephrine as an effective alternative to pseudoephedrine for nasal congestion relief [1][2][3][4].

Topical Nasal Decongestants (Short‑Term Use Only)

• Oxymetazoline and xylometazoline should be limited to a maximum of 3–5 days to avoid rhinitis medicamentosa (rebound congestion) [5][1][2][6][7][8].
• These agents produce rapid nasal vasoconstriction and can provide faster symptom relief than oral decongestants [1][2]4.
• Rebound congestion may appear as early as the third day of continuous use [6][7]8.
• Topical vasoconstrictors must be used with extreme caution in children younger than 1 year because of a narrow therapeutic window and risk of cardiovascular or central‑nervous‑system toxicity [7][8].
• For a 7‑year‑old, short‑term use (≤ 3 days) is acceptable for severe nasal obstruction while other therapies are initiated [5][6][7][8].
• The safety and efficacy of intermittent (non‑daily) topical decongestant use have not been formally studied [1][2][6][7]8.

Combination Products

• Adding an antihistamine to an oral decongestant does not demonstrably increase efficacy for allergic rhinitis in children [1][2][3][4].
• Combination antihistamine‑decongestant products are ineffective for common‑cold symptoms in young children and should generally be avoided [1][2][9][6][7][4].

Safety Thresholds for Decongestant Use

• Over‑the‑counter cough and cold medicines that contain decongestants are not recommended for children under 6 years because of serious safety concerns, including 54 reported fatalities (predominantly in children < 2 years) between 1969 – 2006 [9][6][7][4]8.
• The FDA’s advisory committees advised against OTC cough and cold medications for children < 6 years in 2007 [9][6][7][4]8.
• At age 7, the child has crossed this critical safety threshold, making appropriately dosed decongestant therapy more acceptable [1][10][2][3]4.

Alternative Therapies for Allergic Rhinitis

• Intranasal corticosteroids are the most effective medication class for allergic rhinitis and should be considered first‑line [9][6]7.
• Second‑generation oral antihistamines (e.g., cetirizine, loratadine, fexofenadine) have excellent safety profiles in children and may be preferable for allergic symptoms [9][6]7.
• Intranasal antihistamines (e.g., azelastine, olopatadine) provide rapid relief with an onset of action within 15–30 minutes [10][3].

Safety and Efficacy of Bromfed (brompheniramine + pseudo‑ephedrine) in Children

Regulatory and Safety Recommendations

• The FDA advisory committee advises against the use of over‑the‑counter cough and cold medicines in children younger than 6 years because of serious safety concerns. 11
• In 2007 the FDA’s Nonprescription Drugs and Pediatric Advisory Committees formally recommended that OTC cough and cold products not be used in children under 6 years of age. 11
• Infants aged 6 months to under 2 years have the highest risk of serious adverse events and fatalities when exposed to brompheniramine/pseudo‑ephedrine combinations. 11

Fatalities Reported in Children ≤ 6 years (1969‑2006)

Source: Journal of Allergy and Clinical Immunology, 2008 11

• The most common causes of overdose in this age group are simultaneous use of multiple cold/cough products, dosing errors, and accidental exposures. 11

Evidence of Lack of Efficacy

• Controlled trials have demonstrated that antihistamine‑decongestant combination products do not improve symptoms of upper‑respiratory‑tract infections in young children. 11
• Bromfed should not be used for common‑cold symptoms in children under 6 years; it is ineffective and may be dangerous. 11

Preferred Alternative Therapies

• Intranasal corticosteroids are the most effective medication class for allergic rhinitis and are recommended as first‑line therapy. Evidence from both allergy and otolaryngology societies supports this recommendation. [11][12]
• Second‑generation oral antihistamines (e.g., cetirizine, loratadine, fexofenadine) have excellent safety profiles and are well tolerated in children. [11][12]
• Intranasal antihistamines (e.g., azelastine, olopatadine) provide rapid symptom relief but are not approved for children younger than 5‑6 years. 12

Overdose Prevention

• Never administer multiple cold/cough products at the same time; this practice is a leading cause of accidental overdose. 11
• Always verify the child’s age and weight before dosing and use the measuring device supplied with the medication (general best practice; not directly cited).